Biosimilars | Association for Accessible Medicines
Access! 2020 - Missed the early-bird? Save $300 off full-pass registration when you register by March 27


AAM's Karin Hessler Provides an Inside Look at the GRx+Biosims 2019 Legal Track

Karin Hessler, Assistant General Counsel at the Association for Accessible Medicines, urges attendees to add their voice to the discussion at the one essential generic and biosimilar conference of the year: GRx+Biosims 2019, November 4—6 in Bethesda, MD.

The conference legal track:

AAM's Christine Simmon Talks About Biosimilar Programming at GRx+Biosims 2019

I’m Christine Simmon, Senior Vice President of Policy and Executive Director of the Biosimilars Council at the Association for Accessible Medicines.

Working in this sector, I know how it feels to be inundated with invites to conferences and seminars and workshops and webinars -- all of which are supposed to help you stay on top of biosimilars. It’s a lot!

The House Has Spoken – It’s Time to Fix USMCA’s Pharmaceutical Provisions

In a letter given to U.S. Trade Representative Robert Lighthizer today, 102 members of the House of Representatives expressed strong concern that the pharmaceutical provisions included in the U.S.-Mexico-Canada Agreement (USMCA) – NAFTA 2.0 – could increase prices for medicines in the United States, while limiting the ability of Congress to lessen pharmaceutical monopoly rights.

White Paper (Part 1) Failure to Launch: Patent Abuse Blocks Access to Biosimilars for America's Patients

As prescription drug costs continue to increase, biosimilar medicines represent hope for patients seeking access to more affordable treatment. Biosimilars are lower-priced versions of brand medicines used to treat debilitating and life-threatening diseases, such as Crohn’s disease, ulcerative colitis, cancer and psoriatic arthritis. Patients and physicians can rely on FDA-approved biosimilar medicines just as they would the brand-name product.

NAFTA 2.0: Obstacles to More Affordable Medicines

NAFTA 2.0 (USMCA) will keep drug prices out of reach for American patients.

Patients in the U.S. are already confronted by the world’s longest climb to affordable biosimilar medicines. NAFTA 2.0 (USMCA) will eliminate easier routes and keeps drug prices out of reach for American patients.

The U.S.-Mexico-Canada Agreement (USMCA), the update to the North America Free Trade Agreement (NAFTA), contains provisions that will: 

AAM Statement on FDA Draft Guidance on Biosimilar Naming Requirements

WASHINGTON, DC (March 7, 2019) – “AAM is reviewing the FDA’s new draft guidance on biosimilar naming requirements and will submit comments to the docket. FDA’s current requirement of suffixes presents a significant, artificial barrier to biosimilars that is misaligned with the agency’s own Biosimilars Action Plan and the Trump administration’s commitment to lowering drug prices for America’s patients.”

Subscribe to Biosimilars

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.